Transforming the biopharma industry with quantum computing with Menten AI

The mean cost of developing a new drug has been the subject of debate for many years. A recent study conducted by the London School of Economics estimates a range from 314 million USD to 2.8 billion. And despite the costs varying across different disease areas, it is still a pricey and very lengthy process. In today's episode, we are talking to Tamás Görbe, co-founder and CSO of Menten.AI. Known as one of the most notorious startups using quantum computing in drug research and development. Backed by Y Combinator in 2020, the American startup accelerator which launched Airbnb or Dropbox. The startup uses machine learning and quantum computing to create the next generation of protein-based drugs and enzymes focused on rare diseases, neurological disorders, or viruses.